Preparation method and application of medicine for preventing and treating premature ovarian failure

Abstract

The invention discloses a preparation method and application of a medicine for preventing and treating premature ovarian failure, the medicine comprises the following components in parts by weight: 3-10 parts of eucommia ulmoides, 2-8 parts of salvia miltiorrhiza and 1-6 parts of ligusticum wallichii. The premature ovarian failure (POF) is also called ovarian insufficiency, refers to ovarian function decline, follicle-stimulating hormone level increase and estrogen level decrease of women before 40 years old, and shows secondary amenorrhea and infertility, and is often accompanied with menopausal symptoms such as sweating, insomnia, hypomnesis and the like in a night sleep process; at present, hormone replacement treatment is a main treatment method for premature ovarian failure, but the side effect is large after hormone is taken for a long time, and the probability of suffering from breast cancer and endometrial cancer can be increased; the medicine composition disclosed by the invention can be further developed into a molecular traditional Chinese medicine for preventing POF and delaying the POF process, so that the comprehensive utilization of the composition is promoted, and a new choice is provided for patients with POF.

Description

Technical Field

[0001] The present invention relates to the technical field of premature aging prevention and treatment, and more specifically, to a method for preparing a medicine for preventing and treating premature ovarian failure and its application. Background Art

[0002] Premature ovarian failure (POF) refers to the decline of ovarian function in women before the age of 40, with increased follicle-stimulating hormone levels and decreased estrogen levels, usually manifested as secondary amenorrhea and infertility, often accompanied by menopausal symptoms such as sweating during sleep at night, insomnia, and memory loss. Currently, hormone replacement therapy is the main treatment for premature ovarian failure, but hormone replacement therapy has significant side effects and increases the risk of breast cancer and endometrial cancer. Summary of the invention

[0003] The present invention provides a method for preparing a drug for preventing and treating premature ovarian failure and its application, so as to solve the problem that the hormone replacement therapy for treating premature ovarian failure in the prior art has large side effects and increases the probability of breast cancer and endometrial cancer.

[0004] In order to achieve the above object, the present invention provides the following technical solutions:

[0005] A medicine for preventing and treating premature ovarian failure, comprising eucommia bark, salvia miltiorrhiza and chuanxiong, wherein the proportions of eucommia bark, salvia miltiorrhiza and chuanxiong are eucommia bark: 3-9, salvia miltiorrhiza: 2-7, chuanxiong: 1-5 respectively; and comprising a molecular combination composed of the active ingredients of eucommia bark, salvia miltiorrhiza and chuanxiong, namely aucubin, danshensu, ferulic acid and chlorogenic acid according to their contents in the corresponding proportions of the medicinal materials.

[0006] Preferably, the proportions of Eucommia ulmoides, Salvia miltiorrhiza and Ligusticum chuanxiong are respectively Eucommia ulmoides: 4-10, Salvia miltiorrhiza: 3-8, Ligusticum chuanxiong: 2-6; comprising a molecular combination consisting of the active ingredients of Eucommia ulmoides, Salvia miltiorrhiza and Ligusticum chuanxiong, including aucubin, danshensu, ferulic acid and chlorogenic acid according to their contents in the corresponding proportions of the medicinal materials.

[0007] Preferably, the maximum weight proportion of Eucommia ulmoides in the drug formulation is 80%, and the minimum weight proportion is 10%; the weight ratios of the active ingredients aucubin, chlorogenic acid and ferulic acid contained in the medicinal materials with corresponding weight proportions are included.

[0008] Preferably, the maximum weight proportion of Danshen in the pharmaceutical formulation is 80%, and the minimum weight proportion is 10%, including the weight ratio of danshensu contained in the medicinal materials with corresponding weight proportions.

[0009] Preferably, the maximum weight proportion of Chuanxiong in the pharmaceutical formulation is 40%, and the minimum weight proportion is 5%, including the weight ratio of ferulic acid contained in the medicinal materials with corresponding weight proportions.

[0010] Preferably, a method for preparing a drug for preventing and treating premature ovarian failure comprises the following steps: S1: extraction; S2: concentration; S3: drying.

[0011] Preferably, S1 specifically comprises: boiling all the medicinal materials with water for extraction 2 or 3 times, adding 8 times the volume of water of the medicinal materials for soaking for 30 minutes for the first time, heating and refluxing for extraction for 1-2 hours, and collecting the filtrate for standby use;

[0012] Preferably, S1 specifically includes: adding 6 times the volume of water to the medicinal residue for the second time, heating and refluxing extraction for 0.5-1 hour, and collecting the filtrate for later use; adding 6 times the volume of water to the medicinal residue for the third time, heating and refluxing extraction for 0.5-1 hour, and collecting the filtrate for later use; the heating and reflux extraction process adopted in this feature can also be used as an ultrasonic extraction process.

[0013] Preferably, S2 specifically comprises: combining two or three filtrates, and concentrating the filtrate under reduced pressure at 60-65° C. until the relative density thereof is 1.10-1.15.

[0014] Preferably, S3 specifically comprises: spray drying the filtrate after reduced pressure concentration to obtain dry powder for standby use.

[0015] Preferably, in an application of a drug for preventing and treating premature ovarian failure, the dry powder can be mixed with other conventional excipients to prepare pills, tablets or capsules.

[0016] Preferably, the drug is used in the prevention and treatment of premature ovarian failure (POF).

[0017] Preferably, the drug is used in preventing and treating osteoporosis in menopausal women, preventing and treating senile dementia, improving blood viscosity and protecting cardiovascular and cerebrovascular vessels.

[0018] The principle and beneficial effects of this technical solution:

[0019] (1) Eucommia ulmoides is a good kidney-tonifying medicine, Salvia miltiorrhiza is a good medicine for promoting blood circulation and regulating menstruation, removing blood stasis and promoting regeneration, and Ligusticum chuanxiong is a blood-regulating and qi-regulating medicine. The combination of the three has a synergistic effect and has potential application value in improving POF. Experiments have shown that this formula can improve POF caused by kidney deficiency, blood stasis, and aging by regulating the steroid biosynthesis signaling pathway and the estrogen production pathway, and significantly reduce the degree of aging of the nervous, immune, endocrine, blood, bone, and reproductive systems of POF rats, and can be used to prevent and treat POF.

[0020] (2) This formula alleviated the estrous cycle disturbance, endocrine imbalance, and histopathological changes in POF rats. These results suggest that this formula can be further developed into a molecular Chinese medicine for preventing POF and delaying the POF process. This finding not only promotes the comprehensive utilization of this formula, but also provides a new option for POF patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 The results of monitoring body weight and food intake of POF rats;

[0022] Figure 2 The results of the study and memory ability test of POF rats;

[0023] Figure 3 The results are the measurement results of POF rats' autonomous activity and anti-anxiety emotions;

[0024] Figure 4 The results of the estrous cycle determination of POF rats;

[0025] Figure 5 It is the result of measuring organ index of POF rats;

[0026] Figure 6 The results of the determination of bone biomechanical indices in POF rats;

[0027] Figure 7 The results of the determination of blood rheology indexes in POF rats;

[0028] Figure 8 These are the results of the reproductive system measurements of POF rats;

[0029] Fig. 9 The results of the determination of neuroimmune indexes in POF rats;

[0030] Fig.10 These are the results of the determination of cardiac protection indexes in POF rats;

[0031] Fig.11 These are the results of the determination of endocrine system indicators in POF rats; DETAILED DESCRIPTION

[0032] The present invention is further described in detail below in conjunction with the accompanying drawings and embodiments:

[0033] Example:

[0034] Objective: To explore the efficacy and mechanism of the Zhongdan formula (Bhx) composed of Eucommia ulmoides, Salvia miltiorrhiza and Ligusticum chuanxiong in preventing and treating POF based on tonifying the kidney, activating blood circulation and promoting qi.

[0035] Experimental methods: In this experiment, the kidney deficiency-blood stasis-aging POF rat model was established by natural aging combined with epinephrine, methylprednisolone sodium succinate and ice water bath. Different doses of Bhx were administered by gavage to observe its improving effect on the neuro-immune-endocrine-reproductive circulatory network of POF rats.

[0036] Explanation of synonyms: Eucommia ulmoides (Dz) is a good medicine for kidney tonification;

[0037] Danshen (Ds) is a good medicine for promoting blood circulation, regulating menstruation, removing blood stasis and promoting new blood;

[0038] Chuanxiong (Cx) as a blood-qi medicine;

[0039] Zhongdan Formula (Bhx) is the drug involved in the present invention;

[0040] Experimental steps:

[0041] 1. Combine the three medicinal materials into four different prescriptions, namely

[0042] A: 1000g salt Eucommia ulmoides + 1000g Salvia miltiorrhiza

[0043] B: 1000g salted Eucommia ulmoides + 500g Chuanxiong

[0044] C: Salvia miltiorrhiza 1000g + Ligusticum chuanxiong 500g

[0045] D: Salt Eucommia ulmoides 2000g + Salvia miltiorrhiza 2000g + Chuanxiong 1000g

[0046] The above parties were extracted by the following methods respectively: the medicinal materials were extracted with water twice, the first time 8 times the volume of pure water was added to fully soak for 30 minutes, then heated under reflux extraction for 60 minutes, and the filtrate was collected for later use; the second time 6 times the volume of water was added to the medicinal residue, heated under reflux extraction for 40 minutes, and the filtrate was collected, the two filtrates were combined, concentrated under reduced pressure to a relative density of 1.10-1.15, and spray-dried at 80°C to obtain dry powder for later use.

[0047] Preparation of positive control drug estradiol (Cec) solution: Weigh 0.24 g of estradiol tablet drug powder and place it in a 100 mL volumetric flask, dilute with pure water to prepare a Cec aqueous solution with a final concentration of 2.4 mg / mL.

[0048] Formula and administration group: 15.2g, 5.4g, 15.6g, 8.95g, 17.9g, and 35.8g of Dz-ds powder, Dz-cx powder, Ds-cx powder, and Bhx powder were accurately weighed and placed in a 100mL volumetric flask, and fixed to volume with pure water. The final concentrations were 152mg / mL of Dz-ds solution, 54mg / mL of Dz-cx solution, 156mg / mL of Ds-cx solution, 89.5mg / mL of Bhx low-dose (Bhx-s) solution, 179mg / mL of Bhx medium-dose (Bhx-m) solution, and 358mg / mL of Bhx high-dose (Bhx-L) solution.

[0049] Drug Notes:

[0050] Preparation of methylprednisolone sodium succinate for injection: Take methylprednisolone sodium succinate for injection and add it to normal saline for injection to prepare a solution with a concentration of 16 mg / mL.

[0051] Preparation of epinephrine hydrochloride injection: Take epinephrine hydrochloride injection and prepare it into a 0.6 mg / mL solution with normal saline for injection.

[0052] Preparation of sodium penicillin solution: Take sodium penicillin for injection and add it to normal saline for injection to prepare a solution of 160,000 units / mL.

[0053] The above three drugs are mainly used to establish the POF animal model of kidney deficiency and blood stasis, among which sodium penicillin is used to prevent wound infection caused by repeated injection of drugs during the animal modeling process.

[0054] 2. Animal grouping and drug administration

[0055] The rats with successful modeling were divided into model group (Mod), estradiol group (Cec), Eucommia-Danshen group (Dz-ds), Eucommia-Liangxiong group (Dz-cx), Danshen-Liangxiong group (Ds-cx), low-dose Zhongdanfang group (Bhx-s), medium-dose Zhongdanfang group (Bhx-m), and high-dose Zhongdanfang group (Bhx-L), with 8 rats in each group. Two-month-old female SD rats were used as the normal control group. The drugs were administered by intragastric gavage, with the dosage of each group being Cec 0.024 g / kg, Dz-ds 1.52 g / kg, Dz-cx 0.54 g / kg, Ds-cx 1.56 g / kg, Bhx-s 0.895 g / kg, Bhx-m 1.79 g / kg, and Bhx-L 3.58 g / kg, respectively. The normal control group was given 2 mL of normal saline by intragastric gavage for three consecutive months. The rats were fasted but not deprived of water 12 hours before being killed.

[0056] 3. Detect various indicators of animals

[0057] 3.1 Conventional external feature determination

[0058] The body weight, water intake and food intake of the animals were measured before and after modeling and after administration.

[0059] 3.2 Determination of spatial learning and memory ability

[0060] One week before the end of the experiment, the Morris water maze test was used to measure the spatial learning and memory ability of rats. Adaptive training was performed for 5 days, and the latency and trajectory of the animals finding the platform were recorded. On the 6th day, the platform was removed, and the residence time and trajectory of the animals on the platform were recorded within 60 seconds. The latency, residence time, etc. were recorded and statistical analysis was performed.

[0061] 3.3 Assessment of autonomous activity and psychological status

[0062] The open field test was used to determine the autonomous activity ability and psychological state of rats. The rats were gently placed in the experimental box, and the video acquisition and analysis system was started to record the number of experimental animals crossing the central grid and the number of upright times (vertically divided) in the open field, and statistical analysis was performed.

[0063] 3.4 Determination of estrous cycle

[0064] The estrous cycle of rats was determined by vaginal smear method and Swiss Gim staining.

[0065] 3.5 Organ index and bone strength measurement

[0066] After the administration, the rats were killed, and the brain, thymus, heart, lung, liver, kidney, adrenal gland, uterus, ovary, subcutaneous fat, thoracic vertebrae, and femur were taken and weighed accurately to calculate the organ index and body fat rate. The formula is organ index = organ wet weight / rat body weight * 100%; body fat rate = fat weight / rat body weight * 100%. The femur length was measured, and the bone strength was tested using a small animal bone measuring instrument.

[0067] 3.6 Pathological staining of reproductive system

[0068] The uterine and ovarian tissues of rats were fixed in 4% paraformaldehyde, dehydrated, embedded, sliced, dewaxed, stained, and sealed in sequence, and then the pathological morphological changes of the tissues were observed under a microscope.

[0069] 3.7 Determination of immune system indicators

[0070] Enzyme-linked immunosorbent assay kits were used to detect the levels of CRP, IL-1β, IL-4, TNF-a, and MMP-9 in rat plasma.

[0071] 3.8 Determination of nervous system indicators

[0072] Enzyme-linked immunosorbent assay kit was used to detect the levels of serotonin (5-HT) and norepinephrine (NA) in the plasma of rats in each group.

[0073] 3.9 Determination of endocrine system hormone indicators

[0074] Enzyme-linked immunosorbent assay kits were used to detect the levels of plasma E2, PROG, T, LH, FSH, ACTH and CORT in rats in each group.

[0075] 3.10 Statistical analysis

[0076] All data are expressed as mean ± SEM. Graphpad Prism 8.0 (GraphPad software, Inc., San Diego, California, USA) was used for analysis. SPSS25 statistical software was used for analysis of experimental data. All data were in accordance with normal distribution. One-way ANOVA was used for data. A p value less than 0.05 indicated statistical significance.

[0077] 4. Results

[0078] 4.1 Results of external characteristics of POF rats

[0079] Compared with the animals in the Con group, the amount of water and food consumed by the animals in the Mod group was significantly reduced. Compared with the animals in the Mod group, the amount of food, water and body weight of the animals in each drug-treated group were significantly increased. Bhx-s drug had the strongest effect in promoting animal drinking. The results are shown in Figure 1 .

[0080] 4.2 Results of the measurement of spatial learning and memory ability of POF rats

[0081] Compared with the rats in the Con group, the rats in the Mod group had a significantly longer latency to step onto the stage, and their movement trajectory and average speed were significantly reduced, indicating that their spatial exploration ability was reduced. Compared with the Mod group, the rats in each drug-treated group had a significantly shorter latency, and their movement trajectory and average speed were increased, indicating that drug treatment could improve the spatial exploration ability of POF rats. The results are shown in Table 1. Figure 2 .

[0082] 4.3 Results of the measurement of POF rats’ autonomous activity and anti-anxiety

[0083] Animals with lower anxiety levels tend to spend more time in the center of the open field, i.e., the open area. Compared with rats in the Con group, the number of crossings of the central grid and the number of upright times of the animals in the Mod group were significantly reduced, while the number of crossings of the central grid and the vertical score of the rats in the Bhx group were greatly increased, and the anxiety was significantly improved. The results are shown in Figure 3 .

[0084] 4.4 Results of determination of estrous cycle in POF rats

[0085] The estrous cycle of rats usually includes the following stages: diestrus, proestrus, estrus, and metestrus. Through continuous 12-day estrous cycle detection, it was found that the estrous cycle of rats in the Mod group was disordered. After drug treatment, the estrous cycle of rats returned to normal and showed a certain regularity. The results are shown in Figure 4 .

[0086] 4.5 Results of organ index and body fat percentage measurement in POF rats

[0087] Compared with the animals in the Con group, the indexes of the heart, liver, spleen, lung, kidney, brain, uterus, ovary, thymus, and adrenal glands of the rats in the Mod group were all reduced, and the body fat rate was increased, indicating that the rat organs were atrophic and aging. Compared with the animals in the Mod group, the indexes of the above organs of the rats in each drug-treated group were all increased. The results are shown in Figure 5 .

[0088] 4.6 Results of bone biomechanical parameters in POF rats

[0089] The maximum load and bone strength of the thoracic vertebrae of rats in the Mod group decreased, while the maximum load of the bones of rats in the Cec group, Dz-cx group, Ds-cx group, and Bhx group increased, indicating that Bhx can improve the bone strength of POF rats. Figure 6 .

[0090] 4.7 Results of blood rheology in POF rats

[0091] Compared with the animals in the Con group, the blood status of the rats in the model group was worse, and the blood stasis was more serious; compared with the animals in the Mod group, the blood viscosity and blood rheology indexes of the animals in each drug-treated group were reduced, and the blood status was improved; the Bhx-m group had the strongest effect on reducing the whole blood viscosity 1, the whole blood viscosity 30, and the whole blood low shear relative index, the Bhx-s group had the strongest effect on reducing the whole blood high shear relative index, and the Bhx-L group had the strongest effect on reducing fibrinogen and plasma viscosity. Figure 7 .

[0092] 4.8 Results of the reproductive system tests on POF rats

[0093] The ovaries and uterus of the rats in the Mod group were dark, atrophied and thinned, while the uterus of the rats in the drug-treated group was hypertrophic, and the ovaries were ruddy and normal in morphology, indicating that Bhx can effectively protect the tissue structure of the ovaries and uterus. Pathological staining results showed that there were growing follicles of different developmental cycles in the ovarian tissue of the rats in the Con group, and the cell morphology and cell nucleus of each cell were intact, the granulosa cells were neatly arranged, and the transparent bags and corona radiata in the follicles were obvious. The number of growing follicles at all levels in the ovarian tissue of the rats in the Mod group was significantly reduced, the granulosa cells were chaotically arranged, the oocyte nuclei were condensed, the follicles were sunken, and irregular transparent zones appeared in some. After Bhx treatment, the number of follicles at all levels in the ovarian tissue of the rats increased significantly, and the medium-dose group had the best effect. The granulosa cells were arranged more neatly, the connections were tighter, and the cells were intact. The results are shown in the figure. Figure 8 .

[0094] 4.9 Results of determination of neurological and immune indicators in POF rats

[0095] The levels of NA and 5-HT in the rats in the drug-treated group increased, indicating that the prescription can effectively regulate the synthesis and release of neurotransmitters in rats; the thymus index of rats in the Mod group decreased. Compared with the animals in the Con group, the level of IL-1β in the plasma of the Mod group increased, and the level of IL-4 decreased (P<0.05). Compared with the animals in the Mod group, the thymus index of rats in each drug-treated group increased, the level of IL-1β decreased, and the level of IL-4 increased. Among them, the thymus index of rats in the Bhx-L group increased most significantly, and the degree of increase in IL-4 level in rats in the Bhx group was better than that in the two-combination drug-treated group. The results are shown in Fig. 9 .

[0096] 4.10 Results of determination of cardiac protection indexes in POF rats

[0097] Compared with the rats in the Con group, the levels of SDH and CGMP in the plasma of the rats in the Mod group were significantly reduced. After drug treatment, the levels of SDH and CGMP were significantly increased. Fig.10 , suggesting that Bhx can alleviate the cardiac function decline induced by blood stasis and aging to a certain extent.

[0098] 4.11 Results of determination of endocrine system indicators in POF rats

[0099] Compared with the Con group, the levels of E2, NA, and PROG in the plasma of the Mod group were decreased, and the levels of T, FSH, LH, CORT, and ACTH were increased; compared with the Mod group, the levels of E2, NA, and PROG in the plasma of the Bhx group were significantly increased, and the levels of T and FSH were significantly decreased. Fig.11 .

[0100] 5. Conclusion

[0101] The results of this study indicate that Bhx can improve the functional decline of the nervous-immune-endocrine-reproductive-blood-bone systems, improve the disordered estrous cycle, regulate endocrine imbalance, and alleviate the degenerative pathological changes of ovarian tissue to treat POF caused by kidney deficiency and blood stasis associated with aging. Bhx can be further developed into a molecular Chinese medicine to prevent and delay the process of POF. This discovery not only promotes the comprehensive utilization of Bhx, but also provides a new option for POF patients.

[0102] The above is only an embodiment of the present invention, and the common knowledge such as the known specific technical solutions and / or characteristics in the solution is not described in detail here. It should be pointed out that for those skilled in the art, without departing from the technical solution of the present invention, several modifications and improvements can be made, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the implementation of the present invention and the practicality of the patent. The scope of protection required by this application shall be based on the content of its claims, and the specific implementation methods and other records in the specification can be used to interpret the content of the claims.

Claims

1. A drug for preventing and treating premature ovarian failure, characterized in that: It includes Eucommia ulmoides, Salvia miltiorrhiza and Chuanxiong, wherein the proportions of Eucommia ulmoides, Salvia miltiorrhiza and Chuanxiong are respectively Eucommia ulmoides: 3-9, Salvia miltiorrhiza: 2-7, Chuanxiong: 1-5; it contains a molecular combination composed of the active ingredients of Eucommia ulmoides, Salvia miltiorrhiza and Chuanxiong, including aucubin, danshensu, ferulic acid and chlorogenic acid according to their contents in the corresponding proportions of the medicinal materials.

2. The drug for preventing and treating premature ovarian failure according to claim 1, characterized in that: The proportions of Eucommia ulmoides, Salvia miltiorrhiza and Ligusticum chuanxiong are respectively Eucommia ulmoides: 4-10, Salvia miltiorrhiza: 3-8, Ligusticum chuanxiong: 2-6; it comprises a molecular combination composed of the active ingredients of Eucommia ulmoides, Salvia miltiorrhiza and Ligusticum chuanxiong, including aucubin, danshensu, ferulic acid and chlorogenic acid according to their contents in the corresponding proportions of the medicinal materials.

3. The drug for preventing and treating premature ovarian failure according to claim 1, characterized in that: The maximum weight proportion of Eucommia ulmoides in the drug formulation is 80%, and the minimum weight proportion is 10%; the weight ratios of the active ingredients aucubin, chlorogenic acid and ferulic acid contained in the medicinal materials with corresponding weight proportions are included.

4. The drug for preventing and treating premature ovarian failure according to claim 1, characterized in that: The maximum weight proportion of Danshen in the drug formulation is 80%, and the minimum weight proportion is 10%, including the weight ratio of danshensu contained in the medicinal materials with corresponding weight proportions.

5. The drug for preventing and treating premature ovarian failure according to claim 1, characterized in that: The maximum weight proportion of Chuanxiong in the drug formulation is 40%, and the minimum weight proportion is 5%, including the weight ratio of ferulic acid contained in the medicinal materials with corresponding weight proportions.

6. A method for preparing the drug for preventing and treating premature ovarian failure as claimed in claims 1-5, characterized in that: The following steps are involved: S1: extraction; S2: concentration; S3: drying.

7. The method for preparing a drug for preventing and treating premature ovarian failure according to claim 6, characterized in that: The S1 specifically comprises: adding water to all the medicinal materials and boiling them for extraction 2 or 3 times, adding 8 times the volume of water of the medicinal materials for soaking for 30 minutes for the first time, heating and refluxing for extraction for 1-2 hours, and collecting the filtrate for later use.

8. The method for preparing a drug for preventing and treating premature ovarian failure according to claim 7, characterized in that: The S1 specifically includes: adding 6 times the volume of water to the medicinal residue for the second time, heating and refluxing extraction for 0.5-1 hour, and collecting the filtrate for later use; adding 6 times the volume of water to the medicinal residue for the third time, heating and refluxing extraction for 0.5-1 hour, and collecting the filtrate for later use; the heating and refluxing extraction process adopted in this feature can also be used as an ultrasonic extraction process.

9. The method for preparing a drug for preventing and treating premature ovarian failure according to claim 8, characterized in that: The S2 specifically comprises: combining two or three filtrates, and concentrating the filtrate under reduced pressure at 60-65° C. until the relative density thereof is 1.10-1.

15.

10. The method for preparing a drug for preventing and treating premature ovarian failure according to claim 9, characterized in that: The S3 specifically comprises: spray drying the filtrate after reduced pressure concentration to obtain dry powder for standby use.

11. The use of a drug for preventing and treating premature ovarian failure according to claim 1, characterized in that: The dry powder can be mixed with other conventional auxiliary materials to prepare pills, tablets or capsules.

12. The use of a drug for preventing and treating premature ovarian failure according to claim 1, characterized in that: The drug is used in the prevention and treatment of premature ovarian failure (POF).

13. The use of a drug for preventing and treating premature ovarian failure according to claim 1, characterized in that: The drug is used in preventing and treating osteoporosis in women during menopause, preventing and treating senile dementia, improving blood viscosity and protecting cardiovascular and cerebrovascular vessels.

Images